Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Cutaquig in Primary Immunodeficiency (SCGAM-03)
NCT03907241Phase 3Completed
- Sponsor
- Octapharma
- Start
- Mar 2016
- Primary completion
- Sep 2019
- Modality
- Biologic
- Countries
- 2
01
Overview
A Phase 3 trial of polyvalent human immunoglobulin in primary immunodeficiency (PI), sponsored by Octapharma. Started Mar 2016; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT03907241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03907241.